Femasys shares surge 11.87% intraday after Laidlaw initiates Buy rating with $6.50 target.
ByAinvest
Thursday, Nov 20, 2025 10:31 am ET1min read
FEMY--
Femasys Inc. (NASDAQ:FEMY) surged 11.87% intraday after Laidlaw initiated coverage with a Buy rating and a $6.50 price target, signaling over 750% potential upside from its $0.76 price. The firm highlighted the FemaSeed device’s 17.5% pregnancy success rate (vs. 7% for traditional IUI), its expansion strategy targeting gynecologists, and 63.53% year-over-year revenue growth. Additional catalysts included FDA approval to continue pivotal trials for FemBloc, regulatory progress in Europe, and a Nasdaq compliance update. The report positioned Femasys as undervalued, aligning with the stock’s sharp intraday rally driven by renewed investor confidence in its AI and contraception product pipeline.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet